Mounjaro Cost in Tennessee 2026: Cash Price, Insurance, and Savings Options

What Is the Retail Price of Mounjaro in Tennessee?

The Eli Lilly manufacturer list price for Mounjaro is $1,023 per month across all dose strengths in 2026, and Tennessee retail pharmacies reflect that same figure for cash-paying patients. That price covers a four-pen, once-weekly supply. No significant regional discount exists between Nashville, Memphis, Knoxville, or Chattanooga; the price is effectively uniform statewide because tirzepatide has no generic competitor approved by the FDA as of early 2026 [1].

Why the Price Stays High

Tirzepatide received FDA approval for type 2 diabetes in May 2022 under the brand name Mounjaro [2]. A separate formulation, Zepbound, was approved in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition [3]. Both products share the same active molecule but are marketed separately. Without generic competition, Eli Lilly sets the price, and payers either accept it, impose prior authorization, or exclude it entirely.

How Tennessee Compares to National Averages

The $1,023 Tennessee cash price matches the national list price. Some GoodRx and manufacturer coupon portals advertise lower figures, but those are typically tied to specific insurance adjudication rather than true out-of-pocket cash savings. Patients without insurance who present a GoodRx coupon at a Tennessee pharmacy typically pay between $950 and $1,023 depending on the dispensing chain. The clinical efficacy driving that price is substantial: in the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points and body weight by 12.4 lb more than semaglutide 1 mg at 40 weeks [4].

Does TennCare Cover Mounjaro?

TennCare, Tennessee's Medicaid program, covers Mounjaro only for type 2 diabetes and only after prior authorization requirements are met. It does not cover tirzepatide for weight loss or obesity management as a stand-alone indication. This reflects the broader TennCare preferred drug list policy, which excludes anti-obesity medications from covered benefits except where a comorbid metabolic condition creates a diabetes billing pathway [5].

Prior Authorization Criteria for TennCare

To obtain TennCare coverage for Mounjaro for type 2 diabetes, a prescriber must generally document:

• A confirmed type 2 diabetes diagnosis with an HbA1c above 7.0%
• Trial and inadequate response to at least one preferred agent (typically metformin)
• No contraindication to GLP-1 or GIP/GLP-1 receptor agonist therapy
• Absence of personal or family history of medullary thyroid carcinoma or MEN2 syndrome, per the Mounjaro prescribing label [2]

Prior authorization approvals are typically granted for 12 months and must be renewed annually. The TennCare bureau reviews each renewal against updated HbA1c values and documented medication adherence.

Weight Loss Is Not a Covered Indication

A Tennessee patient who has obesity but no type 2 diabetes cannot obtain Mounjaro through TennCare. Zepbound (the obesity-indicated tirzepatide product) is not on the TennCare preferred drug list as of January 2026. The American Diabetes Association's 2024 Standards of Care describe GLP-1 and dual GIP/GLP-1 agonists as "preferred agents for patients with type 2 diabetes who need weight reduction," but coverage policy and clinical guidance are separate matters [6]. Patients seeking weight-loss coverage should discuss whether a cardiometabolic diagnosis changes their coverage pathway with their prescriber.

Which Commercial Insurance Plans Cover Mounjaro in Tennessee?

Coverage varies by plan. BlueCross BlueShield of Tennessee, Cigna, Aetna, and UnitedHealthcare each maintain individual formularies that change annually, so patients must check their current Summary of Benefits or call member services. The general pattern across these payers in 2026 places Mounjaro on Tier 3 or Tier 4 for type 2 diabetes with prior authorization, and either excludes it entirely for weight loss or places it on a specialty tier requiring step therapy through older agents [7].

Employer-Sponsored Plans

Large self-insured Tennessee employers that use pharmacy benefit managers such as Express Scripts or CVS Caremark may cover Mounjaro under different terms than fully insured plans. Some have added Zepbound to their formulary for obesity with a documented BMI threshold. A 2023 analysis published in JAMA found that only 39% of large U.S. Employer plans covered GLP-1 receptor agonists for obesity, compared with 91% for type 2 diabetes [8]. Employees in Tennessee should request a formulary exception letter from their prescriber if the drug is excluded for weight loss.

Medicare Part D in Tennessee

Medicare Part D plans are permitted to cover anti-obesity medications starting in 2026 under the Inflation Reduction Act provisions, though plan-level adoption varies. Tennessee beneficiaries should check their specific Part D plan's evidence of coverage document. The FDA label for Mounjaro specifies the type 2 diabetes indication, which most Part D plans have covered since 2022 [2].

The Eli Lilly Savings Card: How It Works in Tennessee

The Lilly Mounjaro Savings Card is the single most effective cost-reduction tool for commercially insured Tennessee patients. Eligible patients pay as little as $25 per month for a 28-day supply, with Lilly covering the remainder up to a defined cap. As of 2026, the cap is approximately $573 per month, meaning patients whose insurance adjudicates Mounjaro and leaves a copay of up to $573 may pay only $25 out of pocket [9].

Eligibility Restrictions

The savings card excludes patients covered by any federal or state government health program, including TennCare, Medicare, Medicaid, TRICARE, or the Veterans Affairs system. Tennessee patients on TennCare who are not eligible for the savings card must use other strategies. Patients enrolled in commercial plans through the Affordable Care Act marketplace are generally eligible, provided the plan covers Mounjaro.

How to Activate the Card

Patients can enroll at LillyInsulin.com or through a participating Tennessee pharmacy. The card is presented at point of sale. Pharmacists at CVS, Walgreens, Kroger, and independent Tennessee pharmacies are familiar with the adjudication process. The card must be renewed annually, and Lilly may adjust the benefit terms each calendar year.

Is Compounded Tirzepatide Legal in Tennessee?

Compounded tirzepatide from a state-licensed 503A pharmacy is legal in Tennessee as of January 2026. The FDA placed tirzepatide on its drug shortage list, which opened the door for 503A compounding pharmacies to prepare patient-specific formulations during the shortage period [10]. Tennessee Board of Pharmacy rules allow licensed 503A compounders to dispense compounded tirzepatide with a valid prescription from a licensed prescriber.

503A vs. 503B Compounders

A 503A pharmacy prepares patient-specific prescriptions on a per-order basis. A 503B outsourcing facility manufactures larger batches for distribution to clinics and health systems. Tennessee has both types, though 503B facilities are fewer in number. Compounded tirzepatide from a 503A pharmacy in Tennessee typically costs approximately $249 per month for a clinically comparable dose, significantly below the $1,023 list price for branded Mounjaro [10].

Quality and Safety Considerations

The FDA has issued guidance noting that compounded products are not FDA-approved and do not undergo the same pre-market review for safety, efficacy, and quality as Mounjaro [10]. The Tennessee Board of Pharmacy inspects 503A pharmacies, but batch-to-batch consistency, sterility assurance, and excipient composition may differ from the branded product. Patients choosing compounded tirzepatide should confirm the pharmacy holds an active Tennessee compounding license and ask for a certificate of analysis for each batch.

Regulatory Timeline Risk

The FDA declared tirzepatide no longer in shortage as of a December 2024 notice and gave compounders a wind-down period. Legal challenges from compounding industry groups extended access into 2026, but the regulatory status remains subject to change [10]. A prescriber or telehealth platform operating in Tennessee should be able to provide current guidance on whether 503A compounding remains permissible at the time of a patient's prescription.

Can Tennessee Patients Get Mounjaro via Telehealth?

Yes. Tennessee law permits telehealth prescribing of Mounjaro by a licensed Tennessee physician, nurse practitioner, or physician assistant who has established a valid patient-provider relationship through an audio-video visit [11]. The prescriber must conduct a clinical evaluation sufficient to diagnose type 2 diabetes or obesity and must document the visit in a medical record. A telephone-only visit without video does not meet the Tennessee standard for controlled-substance or specialty medication prescribing in most clinical contexts.

What a Telehealth Visit Should Include

A compliant Tennessee telehealth evaluation for Mounjaro should cover:

• Current HbA1c or fasting glucose for a diabetes indication, or documented BMI for an obesity indication
• Review of contraindications including personal or family history of thyroid C-cell tumors [2]
• Prior medication history and any step-therapy requirements from the patient's insurer
• Discussion of injection technique, titration schedule, and side-effect management

The HealthRX clinical team uses a structured four-domain eligibility screen (metabolic labs, contraindication review, insurance pathway mapping, and patient-reported injection readiness) before completing any tirzepatide prescription for Tennessee patients. This screen reduces prior authorization denials and allows the prescriber to route patients toward the lowest-cost access pathway before the prescription is transmitted.

Telehealth platforms serving Tennessee include national services as well as Nashville-based practices. Patients should verify that the prescribing clinician holds an active Tennessee license searchable through the Tennessee Department of Health license verification portal [11].

What Is the Cheapest Way to Get Mounjaro in Tennessee?

The lowest-cost path depends on a patient's insurance status and diagnosis.

Commercially Insured with Diabetes Diagnosis

A patient with commercial insurance and a type 2 diabetes diagnosis who activates the Lilly savings card pays approximately $25 per month after the card offsets the balance. This is the most cost-effective route for eligible patients. Prior authorization approval typically takes 3 to 10 business days; a peer-to-peer review by the prescribing physician can accelerate denials to approval within 48 hours in many Tennessee plan scenarios.

Uninsured or Underinsured

Uninsured Tennessee patients face the full $1,023 cash price unless they access compounded tirzepatide at approximately $249 per month from a licensed 503A pharmacy. Eli Lilly's Lilly Cares Foundation Patient Assistance Program provides Mounjaro at no cost to patients who meet income criteria, generally at or below 400% of the federal poverty level, with no insurance covering the medication [9]. Applications require income documentation and a provider signature.

TennCare Patients

TennCare patients with a confirmed type 2 diabetes diagnosis should pursue prior authorization through their managed care organization (AmeriHealth Caritas Tennessee, BlueCare Tennessee, or UnitedHealthcare Community Plan). If denied, a formal appeal citing the ADA's 2024 Standards of Care [6] and the SURPASS-2 efficacy data [4] strengthens the clinical record. No savings card or compounding route is available to active TennCare enrollees.

Clinical Efficacy: What Tennessee Patients Should Expect

Understanding the clinical data helps patients set realistic expectations and supports prescribers in documenting medical necessity for insurance purposes.

SURPASS-2 Trial Results

SURPASS-2 (N=1,879) compared tirzepatide at 5 mg, 10 mg, and 15 mg against semaglutide 1 mg in adults with type 2 diabetes inadequately controlled on metformin. At 40 weeks, tirzepatide 15 mg reduced HbA1c by a mean of 2.46 percentage points more than semaglutide and produced 12.4 lb greater weight loss. The difference was statistically significant (P<0.001 for both endpoints) [4]. These results supported the FDA's May 2022 approval and underpin the clinical rationale for TennCare prior authorization requests.

SURMOUNT-1 for Obesity

For patients seeking Mounjaro or Zepbound for weight management, SURMOUNT-1 (N=2,539) showed that tirzepatide 15 mg produced a mean 20.9% reduction in body weight over 72 weeks versus 3.1% for placebo [12]. That magnitude of weight loss rivals bariatric surgery outcomes in short-term comparisons. The FDA approved tirzepatide for obesity management as Zepbound based on these data [3].

Safety Profile

The most common adverse effects of tirzepatide are gastrointestinal: nausea, diarrhea, vomiting, and constipation. In SURPASS-2, nausea occurred in 17% to 22% of tirzepatide-treated patients versus 14% on semaglutide [4]. The prescribing label carries a boxed warning for thyroid C-cell tumors based on rodent studies; the drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 [2]. Tennessee prescribers should screen for these contraindications at the initial visit.

Tennessee-Specific Resources and Next Steps

Tennessee patients have several state-specific access points worth knowing.

The Tennessee Department of Commerce and Insurance maintains a consumer assistance hotline for insurance coverage disputes at (615) 741-2218 [11]. Patients whose commercial insurance denies Mounjaro for a diabetes indication may file a formal appeal or a complaint with the department.

The Tennessee Primary Care Association operates federally qualified health centers (FQHCs) in rural and underserved areas of the state. FQHCs participate in the 340B Drug Pricing Program, which can reduce the cost of Mounjaro for qualifying low-income patients to well below the retail list price [13]. Nashville, Memphis, Knoxville, Chattanooga, and Johnson City each have at least one 340B-participating clinic.

For patients whose HbA1c is borderline or who are pre-diabetic, a telehealth provider can evaluate whether lifestyle intervention data support a diabetes or prediabetes diagnosis that would open a covered pathway. The CDC's National Diabetes Prevention Program lists Tennessee-based lifestyle change programs that serve as documented first-line intervention before a GLP-1 prescription is appropriate [14].

Patients starting tirzepatide should plan a follow-up HbA1c or weight check at 12 weeks to assess response. The ADA 2024 Standards of Care recommend reassessing glycemic targets at each visit and adjusting therapy if HbA1c remains above goal after three months on a stable dose [6].